Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Hansa Biopharma AB (publ)    HNSA   SE0002148817

HANSA BIOPHARMA AB (PUBL)

(HNSA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hansa Biopharma : Nomination Committee formed

11/02/2020 | 02:01am EST

Lund November 2, 2020. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 23, 2020 and has the following composition:
·    Natalie Berner representing Redmile Group 
·    Thomas Olausson  
·    Jannis Kitsakis representing AP4
·    Ulf Wiinberg, Chairman of the Board 

The Chairman of the Board shall also summon the first meeting of the Nomination Committee.
The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.

The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2021 and will be published on Hansa Biopharma's website. 

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to ir@hansabiopharma.com or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326
E-mail: katja.margell@hansabiopharma.com

About Hansa Biopharma
Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, gene therapy and cancer. The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020. Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and also has operations in other European countries and in the U.S.

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-nomination-committee-formed,c3229294

https://mb.cision.com/Main/1219/3229294/1328943.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
HANSA BIOPHARMA AB (PUBL) 0.66% 183.8 Delayed Quote.-23.54%
HANSAE YES24 HOLDINGS CO., LTD 2.28% 7610 End-of-day quote.-0.65%
All news about HANSA BIOPHARMA AB (PUBL)
01/11HANSA BIOPHARMA : Forecasts FY20 Operating Loss to Widen
MT
01/11HANSA BIOPHARMA : provides business update incl. certain key financials ahead of..
AQ
2020HANSA BIOPHARMA :  Biopharma to present at the 39th Annual J.P. Morgan Healthcar..
AQ
2020HANSA BIOPHARMA : Nomination Committee formed
AQ
2020Hansa Biopharma interim report Jan-Sep 2020
AQ
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
PU
2020HANSA BIOPHARMA : Biopharm announces positive high-level data from investigator-..
AQ
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
PU
2020HANSA BIOPHARMA :  Biopharma to host Capital Markets Day on Thursday October 29,..
AQ
2020HANSA BIOPHARMA : certified as a Great Place to Work
AQ
More news
Financials
Sales 2020 35,8 M 4,31 M 4,31 M
Net income 2020 -396 M -47,8 M -47,8 M
Net cash 2020 1 385 M 167 M 167 M
P/E ratio 2020 -19,5x
Yield 2020 -
Capitalization 8 174 M 986 M 986 M
EV / Sales 2020 190x
EV / Sales 2021 74,3x
Nbr of Employees 80
Free-Float 95,9%
Chart HANSA BIOPHARMA AB (PUBL)
Duration : Period :
Hansa Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANSA BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 295,67 SEK
Last Close Price 183,80 SEK
Spread / Highest target 123%
Spread / Average Target 60,9%
Spread / Lowest Target 3,37%
EPS Revisions
Managers and Directors
NameTitle
Søren Tulstrup President & Chief Executive Officer
Ulf Arne Wiinberg Chairman
Christian Kjellman Chief Operating & Scientific Officer
Donato Spota Chief Financial Officer
Achim Kaufhold Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
HANSA BIOPHARMA AB (PUBL)-23.54%986
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059